BREAKING NEWS
Source: Ivermectin and COVID-19  Dec 13, 2020  11 months ago
Yet Another Randomized Trial Shows Ivermectin Effectiveness To Treat COVID-19, This Time By Researchers From Clinica Universidad de Navarra-Spain
Yet Another Randomized Trial Shows Ivermectin Effectiveness To Treat COVID-19, This Time By Researchers From Clinica Universidad de Navarra-Spain
Source: Ivermectin and COVID-19  Dec 13, 2020  11 months ago
Ivermectin to treat COVID-19 in various stages of the disease is turning to be a more viable and proven option despite strong opposition from groups with vested interest in America and Europe.\

This time, a double blind, placebo- controlled randomized clinical trial tested the efficacy of the drug to treat mild conditions of the disease and to see how it prevents high viral loads, how it prevented or reduced symptoms and how it helped the humoral reponse and also prevents disease progression etc. The results were positive and paved the way for larger trials to get Ivermectin to be accepted as a standard treatment protocol.
 
The study was conducted by reseachers from Clinica Universidad de Navarra-Spain, ISGlobal and Inselspital.
 
The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between the "la Caixa" Foundation, academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health. ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. 
 
The study findings were published on a preprint server and are currently being peer-reviewed. https://www.researchsquare.com/article/rs-116547/v1
 
The study team conducted a pilot, randomized, double-blind, placebo-controlled trial to determine the efficacy of a single dose of ivermectin to reduce the proportion of PCR positives, viral load at day 7 post treatment.
 
For the trial, participants were recruited from consecutive patients with confirmed SARS-CoV-2infection and mild COVID-19 (no pneumonia) and no risk factors for complicated disease attending the emergency room of the Clínica Universidad de Navarra. Patients were randomized 1:1 to receive ivermectin, 400 mcg/kg, single dose (n = 12) or placebo (n = 12).
 
The main primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7 post-treatment. The primary outcome was supported by determination of the viral load and infectivity of each sample.  The differences between ivermectin and placebo were calculated using Fisher’s exact test and presented as a relative risk ratio.
 
All COVID-19 patients recruited completed the trial (median age, 26 [range, 18-54] years; 12 [50%] women; 100% had symptoms at recruitment, 70% reported headache, 62% reported fever, 50% reported general malaise and 25% reported cough). At day 7, there was no difference in the proportion of PCR positive patients (RR 0.92, 95% CI: 0.77-1.09, p = 1.0).
 
The ivermectin group had lower median viral loads at days 4 and 7 post treatment as well as lower median IgG titers at day 21 post treatment. Hyposmia/anosmia (76 vs 158 patient-days) and cough (68 vs 97 patient-days) were less frequent in the ivermectin group.
 
Among patients with mild COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 48 h ours of fever or cough onset there was no difference in the proportion of PCR positives. There was however a marked reduction of anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.
 
The positive results from the trial showed that ivermectin merits being used to treat mild SARS-CoV-2 infections as well.
 
Already a randomized trial in India involving healthcare workers showed that it acted effectively as a prophylaxis against the SARS-CoV-2 coronavirus. https://www.thailandmedical.news/news/covid-19-prophylaxis-aiims-study-of-healthcare-workers-in-india-using-ivermectin-as-a-prophylaxis-shows-reduced-covid-19-infection
 
Another randomized trial showed that it was effective to treat severe COVID-19 patients with results even much more promising that U.S. FDA approved drugs like remdesivir that lacks any efficacy and does not improve mortality rates unlike ivermectin. https://www.thailandmedical.news/news/breaking-randomized-multi-center-clinical-trial-shows-that-ivermectin-is-effective-to-treat-covid-19

There have been numerous other observational clinical trials that showed its effectiveness to treat COVID-19.
 
https://www.thailandmedical.news/news/ivermectin-and-covid-19-study-published-in-nature-journal-suggest-that-ivermectin-could-be-a-complementary-antiviral-drug-to-help-treat-covid-19
 
https://www.thailandmedical.news/news/covid-19-drugs-ivermectin-reduces-mortality-rates-in-hospitalized-covid-19-patients-in-a-cohort-clinical-study-conducted-in-south-florida
 
https://www.thailandmedical.news/news/covid-19-drugs-study-shows-that-critical-covid-19-patients-with-lung-injury-requiring-ventilation-benefitted-from-ivermectin
 
Ivermectin first gained importance as a potential pharmaceutical candidate to treat COVID-19 after a research team from Monash University showed that it could inhibit the SARS-CoV-2 coronavirus in vitro studies in early April. https://www.thailandmedical.news/news/must-read-covid-19-drug-research-ivermectin-might-emerge-as-one-of-the-most-suitable-drug-candidates-for-covid-19
 
However there was a concerted effort by the big pharmaceutical companies and even government authorities in America and Europe to ensure that cheaper repurposed generic drugs, herbs and supplements were never promoted to treat COVID-19 as they preferred to promote new expensive drugs that had no efficacy but were in fact toxic as there were financial gains for all vested parties.
 
Unethical researchers from America, Europe and even Australia were paid to discredit therapeutics including ivermectin based on unfounded and unproven reasons such as dosing etc without themselves understanding the pharmacokinetics and mechanisms of the drug.
 
Even despite numerous clinical studies , ivermectin will most unlikely be approved by any regulatory agencies to treat COVID-19 as the big pharmaceutical companies are literally controlling governments, media, social media platforms, search engines and literally everything else.
 
For ethical and properly qualified doctors and individuals who are well researched, they would know what to do and how to request for Ivermectin usage but unfortunately for the ignorant and uneducated, they will be stuffed with the expensive and toxic drugs and made to be indebted to these agencies or their tax monies will be used to satisfy  the greed of the vested parties.
 
Please help share this article as most mainstream media will not cover anything on Ivermectin and also the social media platforms and search engines are now made to lower the feeds of sites that promote research studies on other drugs , herbs and supplements not supported by the vested groups.
 
For more on Ivermectin and COVID-19,  please keep on logging to Thailand Medical News.
 
Please also help to sustain this website and all our research initiatives by making a donation. https://www.thailandmedical.news/p/sponsorship
 
 
 
 
 
 

MOST READ

Feb 05, 2020  2 years ago
Source : Thailand Medical news

FROM MEDICAL THAILAND

LATEST ON HEALTH INSURANCE